AMRX logo

Amneal Pharmaceuticals, Inc.

AMRX
Healthcare|Drug Manufacturers - Specialty & Generic|US
$20.14
+0.69 (+3.55%)
DCF Value
$14.00
Graham Number
$3.96
Cash / Share
$0.47

About

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Stock Price

+72.7%(1Y)
1M
+2.5%
3M
+11.0%
6M
+52.6%
YTD
+59.8%
1Y
+75.4%
3Y
+396.1%
5Y
+283.6%

Pipeline Summary

21 total trials
3
Phase 1
2
Phase 2
13
Phase 3
2
Phase 4
Completed: 11Recruiting: 5Unknown: 4Terminated: 1

Active Trials (5)

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
NCT00404989HIV Infections
Recruiting
Enrollment: 24,258 participants
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668Parkinson Disease
Phase 4Recruiting
Enrollment: 220 participants
Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism
NCT07898072Male Hypogonadism
Phase 3Recruiting
Enrollment: 190 participants
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357Glaucoma, Open-Angle
Phase 3Recruiting
Enrollment: 168 participants
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
NCT07138560Parkinson Disease
Phase 4Recruiting
Enrollment: 22 participants

Key Facts

Market Cap$7.01B
Employees8,500 (+5% YoY)
CEOChirag K. Patel
IPO DateMay 7, 2018
Beta1.25
52-Week Range$11.38 – $21.681
Avg Volume2,762,216
ExchangeNASDAQ
Websiteamneal.com

Ownership

Float45.0%
Shares Outstanding348.3M

Recent Insider Trades

BUCHI J KEVINGIFT
Sep 17, 202620,445 shares
BUCHI J KEVINOPTION EX.
Sep 11, 202620,445 shares @ $14.45
BUCHI J KEVINOPTION EX.
Sep 11, 202620,445 shares @ $14.45
BOYER ANDREW SGIFT
Sep 1, 202680,000 shares
BOYER ANDREW SGIFT
Aug 21, 2026152,426 shares

Peers

AMPHAmphastar Pharmaceuticals, Inc.
$1.21B
ANIPANI Pharmaceuticals, Inc.
$1.55B
BHCBausch Health Companies Inc.
$3.06B
CPIXCumberland Pharmaceuticals Inc.
$78.2M
EBSEmergent BioSolutions Inc.
$310.7M
INDVIndivior Pharmaceuticals Inc
$4.53B
PRGOPerrigo Company plc
$2.20B
RDYDr. Reddy's Laboratories Limited
$12.42B
Data last updated: Nov 9, 2026, 03:54 AM